A U.S. cannabis company, Curaleaf Holdings Inc., has made an unsolicited bid to acquire Aurora Cannabis Inc., based in Edmonton. Aurora announced the formation of a special committee to evaluate the offer, following Curaleaf’s disclosure of its intention to purchase all shares of Aurora.
If successful, the acquisition would result in the creation of a combined cannabis entity operating in 17 countries across Europe, North America, and other global markets. Curaleaf, headquartered in Stamford, Conn., and listed on the Toronto Stock Exchange, decided to publicly reveal its acquisition plan after failed attempts to engage in private negotiations with Aurora’s leadership.
Curaleaf stated that Aurora’s board declined to enter discussions after receiving a formal letter of intent from Curaleaf’s CEO on June 23. Despite a follow-up letter sent on July 7, Aurora allegedly showed reluctance to engage in meaningful talks regarding the proposal.
Expressing disappointment with Aurora’s lack of engagement, Curaleaf emphasized the significant premium and strategic rationale behind the acquisition offer. Curaleaf expressed readiness to collaborate with Aurora’s board to facilitate a value-maximizing transaction swiftly.
Proposing to pay Aurora shareholders $4 US per share and an additional $0.75 US cash for each share, Curaleaf outlined financial terms in its letters dated June 23 and July 7. However, Aurora disputed Curaleaf’s claim that it had disregarded the offer, highlighting ongoing communication between their lead independent director and Curaleaf’s CEO until July 24.
Aurora plans to establish a special committee of independent directors to assess the proposal’s suitability for stakeholders. The company cautioned that reaching a deal is not guaranteed and affirmed its commitment to regular operations during the evaluation process.
While acknowledging Curaleaf’s interest in acquiring Aurora, analysts from TD Cowen expressed concerns that the current offer undervalues Aurora’s future potential. They highlighted Aurora’s market leadership in medical cannabis, robust product portfolio, financial strength, and regulatory expertise as factors that could yield greater value over time.
Curaleaf’s CEO emphasized that merging the companies would leverage Curaleaf’s global distribution network with Aurora’s strong international medical cannabis presence. The combined revenue of over $1.5 billion US in the past year and anticipated annual cost synergies of $40 million US from the acquisition were highlighted as significant benefits for both companies’ shareholders.
